🔬Deep Research

BCRX — BioCryst Pharmaceuticals · catalysts, narrative & risks

·18 sourcesBCRX forecast →

BioCryst Pharmaceuticals (BCRX) — Analysis as of 2026-10-28

Context: BioCryst is a Durham, North Carolina–based biotech building a dual-product hereditary angioedema (HAE) franchise around its oral drug Orladeyo (berotralstat) and the investigable injectable navenibart. As of late October 2026, the stock trades near $8, has a market cap of ~$2.1B, a 52-week range of $6.23–$11.22, a beta of 0.55, and no trailing P/E (TTM EPS of -$1.40) [10]. Below is a point-in-time review; it is not investment advice.

Recent Catalysts (last ~1–3 months)


AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →